Publisher's Note

Publisher's Note

I want to share some exciting news with you. Yesterday we announced the sale of FierceMarkets, our publisher, to Questex Media, a Boston-based B2B media company. Our press release has more details. 

In the near term, you won't see an impact on the FierceMarkets family of Life Science publications. We are still dedicated to bringing you the news and information you need. FierceMarkets will remain independent and continue to be led by the current Washington, DC-based team. Over time, we expect our partnership with Questex to present new opportunities, help us expand coverage, add new features and improve our Fierce products. As always, we will look to you, our community, to tell us how we can help you do your job better. 

Personally, I am excited to continue our strong growth as part of Questex. We are grateful for readers like you, and for everyone who has contributed to our growth. The FierceMarkets team will continue to serve you to our best abilities.

If you have any questions or thoughts about the partnership, drop me a line or leave a comment on the website. I look forward to hearing from you.

Best,
Sean Griffey
Publisher

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.